NEW MJ NEWS

AbbVie to Present at the 10th Annual SVB Leerink Global Healthcare Conference

 

AbbVie (NYSE: ABBV) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present virtually at 9:40 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

View original content:http://www.prnewswire.com/news-releases/abbvie-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-301227093.html

SOURCE AbbVie


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$EAPH Unveils Medicated Markets Revenue Projections for Fiscal 2015

Easton Pharmaceuticals Unveils Medicated Markets Revenue Projections for Fiscal 2015 HUMBOLDT, CA–(Marketwired…

CLS Holdings USA (CLSH) Positioned for Growth in 2019

LAS VEGAS, Dec. 17, 2018 (GLOBE NEWSWIRE) — CLS Holdings USA, Inc.…

Aurora Cannabis Inc. (ACB) Acquires MedReleaf Australia

Aurora Cannabis Acquires MedReleaf Australia Aurora Cannabis Inc. (the “Company” or “Aurora”)…

$GWPH Initiates Second Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome

GW Pharmaceuticals Initiates Second Phase 3 Pivotal Trial for Epidiolex in Dravet…